A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Non-Small-Cell Lung. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Multi-centre Chart Review Study on the Treatment Patterns and Outcomes of Stage I-III Non-Small Cell Lung Cancer in China
Overview
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
Detailed description
The primary objective of this study is to understand the evolution of initial treatment patterns among patients with early-stage (I-III) NSCLC.
Primary outcome measures
- Treatment Patterns [Time frame: Up to 50 months]
- Proportion of unresected patients in SI/II/III [Time frame: Up to 50 months]
- CRT rate in USIII [Time frame: Up to 50 months]
Secondary outcome measures (3)
- Treatment Duration [Time frame: Up to 50 months]
- Patterns of recurrence [Time frame: Up to 50 months]
- Guideline adoption rate [Time frame: Up to 50 months]
Eligibility criteria
Inclusion criteria
- Stage I-III at initial NSCLC diagnosis
- Aged ≥18 years at first diagnosis of NSCLC
- Timeframe of NSCLC diagnosis:
For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027
Exclusion criteria
- NSCLC is not the primary cancer diagnosis
- Patients with a recent history of other tumor or concurrent other tumor
- Patients participating in interventional clinical trials at time of initial diagnosis
- Patients with positive pregnancy status at the time of diagnosis
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Research Site — Beijing
Identifiers
NCT: NCT07316062 · D133FR00236